Association of Caveolin-1 Expression With Prostate Cancer: A Systematic Review and Meta-Analysis

PurposeThe prognostic value of caveolin-1 in prostate cancer remains uncertain. Hence, this meta-analysis was performed to evaluate the prognostic value of caveolin-1 in prostate cancer, as well as ascertain the relationship between caveolin-1 expression and clinicopathological characteristics of prostate cancer patients.MethodsThe PubMed, Embase, Chinese National Knowledge Infrastructure and Chinese Biology Medicine databases were electronically searched to retrieve published studies on caveolin-1 expression in prostate cancer. After study selection and data extraction, the meta-analysis was conducted using Review manager 5.3 software. Odds ratio (OR) with 95% confidence interval (CI) was used to estimate the pooled effect. Funnel plot was used to assess publication bias.ResultsA total of ten studies were enrolled, which included 3976 cases of prostate cancer, 72 cases of high-grade intraepithelial neoplasia (HGPIN), and 157 normal controls. Results of the meta-analysis showed that the positive rate of caveolin-1 expression in prostate cancer was 18.28 times higher than that in normal control (OR= 18.28, 95% CI: 9.02–37.04, p<0.01), and 4.73 times higher than that in HGPIN (OR= 4.73, 95% CI: 2.38–9.42, p<0.01). The relationship between caveolin-1 and clinicopathological characteristics of prostate cancer showed that the differences in caveolin-1 expression in patients with prostate-specific antigen (PSA) >10 vs. ≤ 10 (OR=2.09, 95% CI: 1.35–3.22, p<0.01), differentiation degree low vs. medium/high (OR=2.74, 95% CI: 1.84–4.08, p<0.01), TNM stage T3+T4 vs. T1+T2 (OR=2.77, 95% CI: 1.78–4.29, p<0.01), and lymph node metastasis present vs. absent (OR=2.61, 95% CI: 1.84–3.69, p<0.01) were statistically significant. The correlation analysis between caveolin-1 and the survival time of patients with prostate cancer demonstrated that caveolin-1 was closely related to the prognosis of prostate cancer patients (HR=1.50, 95% CI: 1.28–1.76, p<0.01).ConclusionCaveolin-1 is overexpressed in prostate cancer, which can serve as a risk factor and adverse clinicopathological feature of prostate cancer. Caveolin-1 can also predict poor survival in prostate cancer patients after radical prostatectomy.

Download Full-text

Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis

Clinical Chemistry and Laboratory Medicine (CCLM) ◽

10.1515/cclm-2013-0675 ◽

2014 ◽

Vol 52 (5) ◽

Cited By ~ 64

Author(s):

Giorgio Treglia ◽

Luca Ceriani ◽

Ramin Sadeghi ◽

Giampiero Giovacchini ◽

Luca Giovanella

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Prostate Specific Antigen ◽

Detection Rate ◽

Meta Analysis ◽

Specific Antigen ◽

Choline Pet ◽

Pet Ct

Download Full-text

Prognostic Role of microRNA-155 in Various Carcinomas: Results from a Meta-Analysis

Disease Markers ◽

10.1155/2013/856750 ◽

2013 ◽

Vol 34 (6) ◽

pp. 379-386 ◽

Cited By ~ 12

Author(s):

Jing He ◽

Fengmei Zhang ◽

Ying Wu ◽

Wei Zhang ◽

Xiaoli Zhu ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Prognostic Value ◽

Meta Analysis ◽

Statistical Significance ◽

Prognostic Role ◽

Free Survival ◽

Hazard Ratios ◽

The Relationship

BACKGROUND: Recent studies have shown that microRNAs (miRNA) have prognostic values in cancers. This meta-analysis seeks to summarize the global predicting role of miR-155 for survival in patients with a variety of carcinomas.METHODS: Eligible studies were identified through multiple search strategies. Data were extracted from studies investigating the relationship between miR-155 expression and survival in cancer patients. Combined hazard ratios (HRs) of miR-155 for outcome were analyzed.RESULTS: A total of 16 studies dealing with various carcinomas were included for this meta-analysis. For overall survival, higher miR-155 expression could significantly predict worse outcome with the pooled HR of 2.057 (95% CI: 1.392–3.039). For relapse or progress-free survival, elevated miR-155 was also a significant predictor, with a combined HR of 1.918 (95% CI: 1.311–2.806,). In addition, subgroup analysis showed that higher expression of miR-155 had the trends to predict worse outcome in lung cancer. However, the HRs did not reach the statistical significance.CONCLUSION: Our findings suggest that miR-155 detection has a prognostic value in cancer patients. Regularly measuring miR-155 expression may be useful in clinical practice.

Download Full-text

RELATIONSHIP BETWEEN P53 EXPRESSION AND PSA SERUM

Indonesian Journal of Urology ◽

10.32421/juri.v19i2.56 ◽

2012 ◽

Vol 19 (2) ◽

Author(s):

Ahmad Zulfan Hendri ◽

Danarto HR

Keyword(s):

Prostate Cancer ◽

Serum Level ◽

Cancer Patients ◽

Prostate Specific Antigen ◽

Immunohistochemical Staining ◽

Specific Antigen ◽

P53 Expression ◽

The Mean ◽

The Relationship ◽

Anatomical Pathology

Objective: To know the relationship between p53 expression and prostate specific antigen (PSA) serum level in prostate cancer patients. Material & method: Specimens were studied from patients with pathological diagnosis of prostate cancer in Sardjito Hospital Yogyakarta during 2007 to 2008. The p53 expression was measured by immunohistochemical staining. The stains were done in Department of Anatomical Pathology and examined by a pathologist. The relationship between p53 mutated expression and PSA serum level were analyzed with correlation coefficient (rs). Results: There were 29 patients included in this study. The mean age was 66,34 ± 8,15 (50 - 83) years old. The mean PSA serum level was 165,98 ± 269,208 (1,4 – 1051) ng/ml. The mean number of p53 expression was 111,38 ± 94,30 (16 – 396). There was positive correlation between p53 expression and increasing PSA serum level in the prostate cancer patients (rs + 0,497; p = 0,006). Conclusion: P53 expression was positively correlated with increasing PSA serum level.Keywords: Prostate cancer, p53 expression, PSA serum level.

Download Full-text

Immunohistochemical Determination of ATAD2 Protein Overexpression for Predicting Prognostic Value in Patients with Different Types of Cancer: A Meta-Analysis

Journal of Cancer Biology and Therapeutics ◽

10.18314/gjct.v5i1.1959 ◽

2019 ◽

pp. 280-289

Author(s):

Jiang S ◽

Liu J ◽

Chen X ◽

Zheng X ◽

Ruan J ◽

...

Keyword(s):

Cancer Patients ◽

Meta Analysis ◽

Hepatocellular Cancer ◽

Tumor Stage ◽

Clinicopathological Characteristics ◽

Protein Overexpression ◽

Immunohistochemical Studies ◽

Rr Relative Risk ◽

The Relationship

Background: Increasing number of studies has reported that Atpase family AAA domain-containing 2 (ATAD2) is nuclear coactivator, which is associated with tumor cell proliferation and invasion. Previous studies have demonstrated conflicting results on the relationship between high ATAD2 expression and clinicopathological characteristics of the tumors or patients’ survival outcomes. Considering the discordant results of published studies, we performed a metaanalysis to evaluate the ATAD2 expression in predicting prognosis, and to assess the relationship between high ATAD2 expression and clinicopathological parameters.Methods: We systematically searched electronic database of PubMed, Web of Science and Embase, and selected all immunohistochemical studies of hepatocellular cancer specimens for ATAD2, to analyze the relationship between high ATAD2 expression and prognosis of hepatocellular cancer patients. Pooled data of eligible studies together from individual studies and analyzed data using STATA software to perform this meta-analysis.Results: A total of 5 studies with 719 liver cancer patients were included. ATAD2 protein overexpression wassignificantly correlated with poorer overall survival (HR 3.53, 95% CI: 1.87-6.63, P = 0.000). In addition, high ATAD2 expression was also negatively related with tumor stage [RR, relative risk: 1.46 (95% CI: 1.30-1.64); P < 0.001], as well as tumor size [RR: 1.23(95% CI: 1.06-1.43); P < 0.001], and tumor recurrence [RR: 1.34 (95% CI: 1.05-1.72); P < 0.001].Conclusions: These data suggested that immunohistochemical determination of ATAD2 Protein might be aprognostic biomarker for the patients of hepatocellular cancer.

Download Full-text

1639 THE PROGNOSTIC VALUE OF PATHOLOGIC PROSTATE-SPECIFIC ANTIGEN MASS RATIO IN LOCALIZED PROSTATE CANCER PATIENTS WITH NEGATIVE SURGICAL RESECTION MARGIN

The Journal of Urology ◽

10.1016/j.juro.2012.02.1456 ◽

2012 ◽

Vol 187 (4S) ◽

Author(s):

Sangchul Lee ◽

Jong Jin Oh ◽

Cheol Yong Yoon ◽

Chang Wook Jeong ◽

Seong Jin Jeong ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Prostate Specific Antigen ◽

Surgical Resection ◽

Prognostic Value ◽

Resection Margin ◽

Specific Antigen ◽

Localized Prostate Cancer ◽

Mass Ratio ◽

Surgical Resection Margin

Download Full-text

The Evaluation of PSA levels in Libyan Prostate Cancer Patients

Clinical Oncology Research and Reports ◽

10.31579/2693-4787/029 ◽

2022 ◽

Vol 3 (1) ◽

pp. 01-05

Author(s):

Omar Alqawi ◽

Eman Elshahmi ◽

Fatma Emaetig ◽

Fauzia Elgaraboli ◽

Abubaker Abushnaf

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Gleason Score ◽

Specific Antigen ◽

Developed Countries ◽

P Value ◽

Prostate Cancer Mortality ◽

Psa Testing ◽

The Developed Countries ◽

The Relationship

Background: Prostate cancer is the second most frequent cancer and the fifth leading cause of cancer death in men with higher prevalence in the developed countries. The use of biomarkers for prostate cancer can improve the diagnosis of prostate cancer and clinical management of the patients. Prostate-specific antigen (PSA) is widely used to screen for prostate cancer and there is evidence that PSA testing reduces prostate cancer mortality. Objective: In this report we have studied the relationship between the Gleason score, age and PSA levels of prostate adenocarcinoma tissues from Libyan patients to evaluate the levels of PSA in prostate cancer patients. Materials and methods: The data was collected from medical files of 40 patients who underwent curative surgical prostatectomy or prostate true cut biopsy at National Cancer Institute (NCI)-Misurata, Libya during 2016 to 2018. The clinical and histopathological information included age, PSA levels, and Gleason score grade. Results: Our data showed that PSA level was statistically significant correlation with Gleason score grade (p- value = 0.007, <0.05). The increased serum PSA level was associated with the progression of prostate cancer. However, we found no statistically significant correlation between PSA and the age of patients (p- value = 0.435). Conclusion: Our data confirmed the association of high levels of PSA and the progress of prostate cancer.

Download Full-text

Impact of Matrix Metalloproteinase-11 Gene Polymorphisms on Biochemical Recurrence and Clinicopathological Characteristics of Prostate Cancer

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph17228603 ◽

2020 ◽

Vol 17 (22) ◽

pp. 8603

Author(s):

Chun-Yu Hsieh ◽

Ying-Erh Chou ◽

Chia-Yen Lin ◽

Shian-Shiang Wang ◽

Ming-Hsien Chien ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Matrix Metalloproteinase ◽

Cancer Patients ◽

Biochemical Recurrence ◽

Specific Antigen ◽

Clinicopathological Characteristics ◽

Gleason Grade ◽

Advanced Tumor Stage ◽

Advanced Tumor

Prostate cancer is among the most common malignant tumors worldwide. Matrix metalloproteinase (MMP)-11 is involved in extracellular matrix degradation and remodeling and plays an essential role in cancer development and metastasis. This study investigated the association of MMP-11 polymorphisms with the clinicopathological characteristics and biochemical recurrence of prostate cancer. Five single-nucleotide polymorphisms (SNPs) of the MMP-11 were analyzed in 578 patients with prostate cancer through real-time polymerase chain reaction analysis. A prostate-specific antigen level of >10 ng/mL, Gleason grade groups 4 + 5, advanced tumor stage, lymph node metastasis, invasion, and high-risk D’Amico classification were significantly associated with biochemical recurrence in the patients (p < 0.001). MMP-11 rs131451 “TC + CC” polymorphic variants were associated with advanced clinical stage (T stage; p = 0.007) and high-risk D’Amico classification (p = 0.015) in patients with biochemical recurrence. These findings demonstrate that MMP-11 polymorphisms were not associated with prostate cancer susceptibility; however, the rs131451 polymorphic variant was associated with late-stage tumors and high-risk D’Amico classification in prostate cancer patients with biochemical recurrence. Thus, the MMP-11 SNP rs131451 may contribute to the tumor development in prostate cancer patients with biochemical recurrence.

Download Full-text